Ratan Capital bounces back in 2020 after years of curve balls By Reuters

2/2
© Reuters. FILE PHOTO: A Specialist trader watches his chart while working on the floor of the New York Stock Exchange

2/2

By Svea Herbst-Bayliss

BOSTON (Reuters) – A few years ago, Ratan Capital Management faced questions of survival due to bad bets that shriveled its capital and its founder settling regulatory charges about information sharing.

Now, the hedge fund is back in the spotlight after posting stellar returns last year that might help lure new investors.

Ratan Capital, run by Nehal Chopra, delivered a 98% return in 2020, its best ever, thanks to long-held investments in companies that provide business solutions, according to a letter sent to investors and seen by Reuters.

Its performance trounced the average hedge fund’s 11.6% return, as well as the , which gained 16% last year.

Investments in Vertiv Holding Co, RingCentral (NYSE:) Inc and Clarivate PLC were the biggest winners, all posting double-digit gains, Chopra wrote. They more than offset losses from online ticket-ordering business Trainline PLC and health-insurance claims processor Multiplan Corp.

Chopra declined to comment.

It is too early to know whether the outsize returns lead to fresh capital, but Ratan’s performance is the latest in a series of dips and rebounds for the firm. One of a handful of women to run their own hedge funds, investors saw Chopra as a rising star when she started Ratan in 2009. It was a difficult time to launch because of industry losses during the financial crisis, but she secured backing from major investors including Tiger Management founder Julian Robertson.

Strong early results helped swell Ratan’s assets to roughly $1 billion by 2015. Despite ups and downs, its long-term performance has been strong, with an average 16% return over 10 years and an average 35% return per year over the last three years.

However, Ratan joined prominent hedge fund managers, including Pershing Square Capital Management’s William Ackman, to invest in pharmaceutical firm Valeant – which turned out to be a disastrous bet. Now called Bausch Health Companies (NYSE:) Inc, the investment seriously harmed Ratan’s performance in 2015.

Then, in December 2017, Chopra settled with the U.S. Securities and Exchange Commission over alleged inappropriate information-sharing with her husband, Paritosh Gupta, who worked at a different fund. Soon after, Robertson and other investors exited. Ratan now has $350 million in assets under management.

Whether last year’s eye-popping performance translates into fresh cash remains to be seen. Since the financial crisis, investors have become increasingly skittish, often preferring big-name funds with smaller but steadier returns.

In her letter, Chopra thanked investors who stuck with her over time, and warned that this year will likely be “bumpy.”

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*